ARTICLE | Company News
GenVec, National Institutes of Health deal
February 28, 2000 8:00 AM UTC
GenVec received exclusive rights to the pigment epithelium derived factor (PEDF) gene from NIH for use in treating blindness. The company said PEDF is an antiangiogenic factor that could potentially ...